Full-Time
Intake Coordinator
Posted on 10/31/2025
Local Infusion
51-200 employees
Ambulatory infusion centers for chronic therapies
Compensation Overview
$25/hr
Dulles, VA, USA
In Person
 Operations & Logistics (1) |
|---|
- Health Care Experience Required
- Insurance Prior Authorization Experience
- Medical Terminology Experience
- Overall Medical Insurance Experience
- Ability to quickly grasp new apps
- Experience and strong familiarity utilizing Electronic Health Records (EHR) systems
- Handle all aspects of the infusion referral process; obtaining authorizations, financial counseling, benefit investigation
- Liaison with referring providers to obtain documentation necessary for treatment, and communicate status of their patients
- Communicate referral process and status to patients in a customer-centric way
- Openly communicate with referring/prescribing providers
- Assist in maintaining medical inventory and office supplies
- Dedicated 1 on 1 training for 6 weeks to help you succeed in your role
- Prior Experience in Infusion is Preferred
Local Infusion operates ambulatory infusion centers and coordinates infusion and injectable therapies for chronic autoimmune diseases like Crohn’s, MS, and rheumatoid arthritis. It uses a proprietary AI-powered platform to streamline referrals and care coordination, plus patient tools for scheduling, pricing transparency, and financial assistance. The approach reduces administrative work for clinicians and lowers overall costs, with centers offering private suites and flexible hours to improve patient experience. The company aims to expand accessible, affordable infusion care outside hospitals while growing its network and keeping personalized patient support.
Company Size
51-200
Company Stage
Series A
Total Funding
$14M
Headquarters
Nashville, Tennessee
Founded
2022
Simplify's Take
What believers are saying
- Projected largest U.S. infusion provider by 2028 with 300+ locations.
- QIVIGY exclusive distribution partnership expands Primary Humoral Immunodeficiency patient access.
- Administers 150+ medications for 75+ conditions including oncology immunotherapies.
What critics are saying
- Uptiv's superior telehealth-biologic integration captures physician referrals within 6-12 months.
- Kedrion expands QIVIGY distribution to larger chains, reducing Local Infusion's PI volume.
- FDA site-of-care mandates force referral of 40% high-risk biologics to hospitals.
What makes Local Infusion unique
- AI-driven platform reduces physician administrative burden by three hours per referral.
- Delivers infusion care at 2-3x lower cost than hospital-based alternatives.
- 98% patient satisfaction score across 45+ locations with spa-like amenities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Parental Leave
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -3%Specialty infusion clinic announces Creekside Station as its first Winchester location. Local Infusion, a Nashville-based specialty infusion provider with more than 45 locations nationwide, will open its first Winchester clinic at Creekside Station in March. The new site marks the company's 12th location in Virginia. The provider has leased 2,962 square feet at the 126,304-square-foot lifestyle center, owned by Continental Realty Corporation (CRC). CRC's Kelsi Holman represented the landlord alongside Segall Group brokers Andrew Lynch and Andy Segall, while Billy Orlove of The Shopping Center Group represented the tenant. "Adding Local Infusion strengthens Creekside Station's growing mix of health and wellness providers," said Kristina O'Keefe, Senior Vice President of Retail Operations at CRC. Local Infusion delivers patient-centered care for a range of chronic conditions, including asthma, multiple sclerosis, and lupus, using an AI-driven platform designed to speed up treatment access. "Our new Winchester clinic expands infusion care options and supports local health systems," said CEO Woody Baum, noting the site's convenient location and accessibility. Located at 3103 Valley Avenue, Creekside Station is a 13-acre retail center featuring a mix of shops, restaurants, and services, with strong surrounding demographics and traffic. The property is part of the larger Creekside Town Center mixed-use community, which includes office space and new residential development underway. Full article from CityBiz here.
Local Infusion joins the QIVIGY(R) limited distribution network as the first Ambulatory Infusion Center. Local Infusion will expand its infusion offerings with the addition of QIVIGY(R)(Immune Globulin Intravenous, human-kthm) 10% liquid from Kedrion Biopharma NASHVILLE, Tenn. - Local Infusion, the fastest growing ambulatory infusion provider in the United States, today announced it is joining Kedrion Biopharma's limited distribution network for QIVIGY (immune globulin intravenous, human-kthm), a 10% intravenous immunoglobulin (IVIG) solution to treat adults with Primary Humoral Immunodeficiency (PI). QIVIGY was approved by the FDA in late 2025 and will be available for use in March 2026, giving patients a new option to replace deficient antibodies and reduce infection rates. Kedrion Biopharma selected Local Infusion for its unique capability to bring together infusion data, intelligent automation, and programmable care pathways to help patients get treated quicker, improve treatment adherence, and ultimately deliver better patient outcomes. "At Kedrion, our dedication to those affected by rare diseases drives everything we do," said Lynda Bowe, Vice President Corporate Accounts of Kedrion. "Working with Local Infusion, we are united in our goal to make QIVIGY available to more people living with Primary Humoral Immunodeficiency across more communities. Together, we can help ensure that patients get the therapies they need more conveniently and reliably." "Kedrion's decision to name Local Infusion as the first Ambulatory Infusion Center in its limited distribution network for QIVIGY is a testament to the high quality of care our patients receive," said Ashley Knapp, Co-Founder and Chief of Staff at Local Infusion. "Through this limited distribution network, patients receiving QIVIGY have a convenient, comfortable option that gets them to treatment faster." By joining the QIVIGY limited distribution network, Local Infusion continues to expand its patient-centered programs accelerating speed to treatment and patient outcomes in collaboration with manufacturers, healthcare providers, health systems, and payors nationwide. About Local Infusion Local Infusion is a leading health care and technology company dedicated to transforming the specialty infusion industry, because patients deserve better. By combining comfortable, patient-centered clinical care with a proprietary, AI-driven technology platform, Local Infusion accelerates access, simplifies workflows, and improves outcomes for everyone in the infusion journey - from patients and clinicians to health plans, health systems, employers, and pharma. With Local Infusion, every patient and every care team is fully supported, every step of the way. Learn more at www.mylocalinfusion.com. Local Infusion Media Contact Riley Steinmetz VP of Marketing [email protected]
Specialty Pharmacy news roundup: march 2026. The following are just a few of the many recent specialty pharmacy activities this past month. You can find even more news and insights by subscribing to AMI's Specialty Pharmacy Database. AOM Infusion, a leading provider of specialty infusion care and pharmacy services, announced that it has earned the Distinction in Immunoglobulin (Ig) Therapy from the Accreditation Commission for Health Care (ACHC) in collaboration with the Immunoglobulin National Society (IgNS). This distinction is designed to identify immunoglobulin therapy centers of excellence, and AOM is proud to be among the first infusion therapy providers nationwide to receive it. AOM Infusion announced it has joined Kedrion Biopharma's limited distribution network for QIVIGY, a new 10% immune globulin (Ig) liquid indicated for treatment of adults with Primary Humoral Immunodeficiency (PI). The addition of QIVIGY expands AOM's immune globulin portfolio and strengthens its ability to help patients and providers access innovative therapies for complex immune disorders. This announcement builds on AOM's recent collaboration with Kedrion for YIMMUGO, a 10% immune globulin liquid also indicated for the treatment of PI. CarepathRx announced a new statewide Ancillary Agreement with Humana Healthy Horizons in Ohio. This partnership significantly expands CarepathRx's reach, allowing the company to provide Home Infusion Therapy, Specialty Infusions, and Enteral Nutrition services to Medicaid members throughout the entire state. This collaboration reflects its ongoing commitment to delivering high-touch specialty pharmacy care exactly where patients need it most. Local Infusion, the fastest growing ambulatory infusion provider in the United States, announced it is joining Kedrion Biopharma's limited distribution network for QIVIGY (immune globulin intravenous, human-kthm), a 10% intravenous immunoglobulin (IVIG) solution to treat adults with Primary Humoral Immunodeficiency (PI). Lumicera Health Services, a leading specialty pharmacy solutions provider and Top 10 national specialty pharmacy, announced that it has earned URAC's Rare Disease Pharmacy Center of Excellence Certification. This premier, evidence-based certification recognizes specialty pharmacies demonstrating exceptional, high-touch care and advanced capabilities serving patients with rare and complex conditions. The designation builds on Lumicera's existing URAC Specialty Pharmacy Accreditation, further validating Lumicera's commitment to exceeding expectations for patients requiring specialized therapies and individualized support. Onco360, the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI (relacorilant), which is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Transition Pharmacy, Regalo Health's direct-to-patient pharmacy, has relocated its primary fulfillment operations from Trevose, Pennsylvania, to a new 18,000-square-foot purpose-built facility at 100 Corporate Drive in Montgomeryville. The move expands capacity and strengthens its ability to deliver timely, high-quality care nationwide. Located in a well-connected regional logistics hub, the new facility supports more efficient shipping coordination and improved on-time delivery performance. The expanded space is designed for high-volume pharmacy operations with enhanced infrastructure. UVA Health has opened Pharmacy Central Services - a critical hub for UVA Health University Medical Center including UVA Health Children's; and UVA Health Culpeper, Haymarket, and Prince William Medical Centers in Northern Virginia. Continuing to support all three of its UVA Health strategic plan goals of expanding its excellence, cultivating healthy communities, and strengthening its foundation - Pharmacy Central Services widens its reach across Virginia, and to more than a dozen other states from Florida to Massachusetts.
/PRNewswire/ -- Tinsley Medical Practice Brokers is pleased to announce the successful sale of Carolina Neurology of Spartanburg, LLC to Local Infusion, a...
Like this story? Please share!News & Notes | 200 applicants choose Techstars Knoxville as #1 or #2 Pete Nelson, President of AgLaunch, is one of the speakers during the first day of the SBA's virtual "2023 Innovation Ecosystem Summit" set for next week.From Knoxville:Brandon Bruce, Managing Director of the “Techstars Industries of the Future Accelerator,” reports that exactly 200 applications were received for the third cohort by Wednesday’s deadline. “About half of the applicants listed ‘Industries of the Future’ as their primary preference,” he said. “For these applications, we get first dibs on outreach. For the other half, we’re the alternate preference. We can reach out to them after two weeks and after speaking with the primary program to verify a warm handoff.”Bruce said that the next step in the selection process is scheduling 30-minute initial interviews with the roughly top 40 applicants that he and his team have judged to be the best fits.The three-month accelerator begins March 11, and Bruce and his team are planning a public event to introduce the participants to the community the next week. “Demo Day” is June 6.Another from Knoxville:Keeton Ross, Co-Founder and President of Holocene Climate Corporation, has been named to the latest “Forbes 30 Under 30” listing in the energy category